NCT02475161View on ClinicalTrials.gov

A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Healthy
Interventions
DRUG

JNJ-42847922

JNJ-42847922 will be administered as 20 mg tablet orally.

DRUG

Rabeprazole

Rabeprazole will be administered as 20 mg tablet orally.

Trial Locations (1)

Unknown

Overland Park

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02475161 - A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants | Biotech Hunter | Biotech Hunter